Promoting scientific careers in times of COVID-19 Blog Post

Against the backdrop of the major challenges posed by the COVID-19 pandemic, which has underscored the crucial role science and technology play in our society, the Barcelona Science Park is stepping up its commitment to persuading young people to choose scientific careers by holding a new edition of Batx2Lab, a pioneering programme which has inspired the STEM talent of more than 700 young people.

 

Gorka Etxebarria, new Chief Scientific Officer of Nostrum Biodiscovery Blog Post

Nostrum Biodiscovery (NBD) has appointed Dr. Gorka Etxebarria as new Chief Scientific Officer. Dr Etxebarria has a solid career linked to drug discovery projects in the pharmaceutical industry. His incorporation comes after the signing of Ezequiel Mas as new company CEO, to pilot a new stage of growth as a global provider of leading molecular simulation technologies applied to drug discovery and design.

 

Juan Carlos Kaski, new Chief Medical Officer of GlyCardial Diagnostics Blog Post

GlyCardial Diagnostics, based in the Barcelona Science Park, announces the appointment of Prof. Juan Carlos Kaski as Chief Medical Officer. The company –a spinoff of the Research Institute of the Hospital de la Santa Creu i Sant Pau (IR-HSCSP) and the Spanish National Research Council (CSIC), is conducting a clinical trial to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of Myocardial Ischaemia.

 

The PCB’s scientific community joins the fight against SARS-CoV-2 Blog Post

In response to the health emergency caused by SARS-CoV-2, research centres and biotech companies in the Barcelona Science Park (Parc Científic de Barcelona, PCB) are leading scientific progress in the treatment, vaccination and diagnosis of the novel coronavirus. The PCB will ensure that public centres and businesses can continue with their research projects by providing the resources and services they need.

 

The European project GLAM develops a multiplexed biosensor for personalized diagnosis and therapy for bladder cancers Blog Post

A European consortium led by Centre Tecnològic Leitat –through its Biomed Division in the Barcelona Science Park (PCB)– has finished the GLAM project, the aim of which was to develop a photonic biosensor for a non-invasive diagnosis and personalized therapy for bladder cancers. The project involved the participation of 10 European organizations with resources and capabilities from the academia and scientific and business field, among them the Institute for Bioengineering of Catalonia (IBEC), which is also located in PCB.

 

GlyCardial Diagnostics wins the EmprendedorXXI 2019 Award in the ‘Health Tech’ category Blog Post

GlyCardial Diagnostics has won the  the EmprendedorXXI Award in the ‘Health Tech’ category, one of the six awards granted in its twelfth year to recognize those companies in Spain and Portugal with greatest growth potential in several sectors linked to the new innovation trends. The winners have been selected from 961 companies in Spain and Portugal. The biotechnology company, headquartered in the Barcelona Science Park, adds this award to the EmprendedorXXI Award in Catalonia, which it received on 9 May.

 

Whole Genix receives the 2019 ‘Medicina Siglo XXI’ Award for Medical Innovation Blog Post

The company Whole Genix, based in the Barcelona Science Park, received the 2019 ‘Medicina Siglo XXI’ Award in the Medical Innovation category during the gala marking the II edition of these prizes, held on Friday in Hotel Arts in Barcelona. With these awards, the editorial group El Suplemento aims to value the professional, scientific and innovative talent of professionals who work for and for health in various specialties and from different Spanish cities.

 

IBEC, ISGlobal and Bioiberica join forces to study new strategies based on nanomedicine to combat malaria Blog Post

The Institute for Bioengineering of Catalonia (IBEC), the Barcelona Institute for Global Health (ISGlobal) and the biotech firm Bioiberica have signed a partnership agreement to study the development of new compounds derived from heparin to combat malaria. The partnership, which was officially announced this morning at the international Biospain meeting held in Bilbao.

 

UL Acquires AWS Truepower to expand global renewable energy portfolio Blog Post

UL (Underwriters Laboratories), a global safety science leader, announces the acquisition of  AWS Truepower, a leading energy engineering services and advisory firm. This achievement expands UL’s global renewable energy portfolio by strengthening full lifecycle solutions for wind and solar energy sectors. AWS Truepower operates in Europe and Latin America through AWS Truepower SLU, a spanish company located at the Barcelona Scientific Park (PCB).